Table 2 Characteristics of patients in the persisted group.

Patient	Age	Sex	Location of classic CNV	Relation of classic CNV to polypoidal lesion	LS (μm)	PDT treatments, n	BCVA at baseline	BCVA at final visit	Follow‐up duration (months)
15	81	M	Subfovea	Adjacent	2900	2	20/100	20/130	21
16	73	M	Subfovea	Separated	770	4	20/200	20/200	21
17	72	M	Juxtafovea	Adjacent	2400	4	20/40	20/130	20
18	53	F	Subfovea	Adjacent	3100	3	20/100	20/130	20
19	67	M	Subfovea	Separated	2200	2	20/200	20/130	19
20	73	M	Subfovea	Adjacent	2880	2	20/200	20/100	18
21	66	M	Subfovea	Adjacent	2850	2	20/70	20/300	18
22	74	M	Subfovea	Separated	4200	2	20/400	20/200	15
23	73	M	Subfovea	Adjacent	2850	3	20/100	20/100	14
24	72	M	Subfovea	Separated	3300	3	20/100	20/100	14
25	73	M	Subfovea	Separated	4400	1	20/200	20/200	14
26	79	M	Juxtafovea	Adjacent	1710	1	20/100	20/70	13
27	73	M	Subfovea	Adjacent	5400	1	20/300	20/500	13
28	68	M	Subfovea	Separated	4720	1	20/40	20/50	13
29	74	F	Subfovea	Adjacent	2000	2	20/200	20/250	12
30	72	M	Subfovea	Separated	3550	3	20/50	20/70	12
31	75	M	Subfovea	Adjacent	2100	1	20/200	20/200	12
32	80	M	Subfovea	Adjacent	3600	1	20/500	20/250	11
33	74	F	Subfovea	Adjacent	2310	2	20/130	20/100	10
34	63	F	Subfovea	Adjacent	3560	2	20/500	20/200	10
35	72	M	Subfovea	Separated	3700	1	20/100	20/100	9
36	55	F	Juxtafovea	Separated	4500	2	20/40	20/130	8
37	58	F	Subfovea	Separated	1500	1	20/100	20/70	7
38	79	M	Subfovea	Adjacent	4500	1	20/100	20/100	6

CNV, choroidal neovascularisation; LS, lesion size; PDT, photodynamic therapy; BCVA, best‐corrected visual acuity.

Adjacent, adjacent to polypoidal lesions; separated, separated from polypoidal lesions.